ArticleLab on a chip2017
An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport.
Article in Lab on a chip, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Engineering the oxygen microenvironment for pancreatic islet transplants.NPJ Regenerative medicine · 2026Review
- Oxygen dynamics and delivery strategies to enhance beta cell replacement therapy.American journal of physiology. Cell physiology · 2025Review
- A computational algorithm for optimal design of a bioartificial organ scaffold architecture.PLoS computational biology · 2024Article
- Advances in modeling permeability and selectivity of the blood-brain barrier using microfluidics.Microfluidics and nanofluidics · 2024Article
- Encapsulation and immune protection for type 1 diabetes cell therapy.Advanced drug delivery reviews · 2024Review
- Status of islet transplantation and innovations to sustainable outcomes: novel sites, cell sources, and drug delivery strategies.Frontiers in transplantation · 2024Review
- Characterization of human islet function in a convection-driven intravascular bioartificial pancreas.Bioengineering & translational medicine · 2023Article
- Surface Engineering of a Bioartificial Membrane for Its Application in Bioengineering Devices.ACS omega · 2023Review
- Mathematical and Computational Modeling of Poroelastic Cell Scaffolds Used in the Design of an Implantable Bioartificial Pancreas.Fluids (Basel, Switzerland) · 2022Article
- The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?Frontiers in endocrinology · 2022Review
- Superporous agarose scaffolds for encapsulation of adult human islets and human stem-cell-derived β cells for intravascular bioartificial pancreas applications.Journal of biomedical materials research. Part A · 2021Article
- Modulating the foreign body response of implants for diabetes treatment.Advanced drug delivery reviews · 2021Review
- AnFrontiers in bioengineering and biotechnology · 2021Article
- Enabling allogeneic therapies: CIRM-funded strategies for immune tolerance and immune evasion.Stem cells translational medicine · 2020Review
- Engineering Strategies to Improve Islet Transplantation for Type 1 Diabetes Therapy.ACS biomaterials science & engineering · 2020Article
- Engineering the vasculature for islet transplantation.Acta biomaterialia · 2019Review
- Nanotechnology in cell replacement therapies for type 1 diabetes.Advanced drug delivery reviews · 2019Review
- Sterilization effects on ultrathin film polymer coatings for silicon-based implantable medical devices.Journal of biomedical materials research. Part B, Applied biomaterials · 2018Article
- Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.Cell stem cell · 2018Review
- Current Status and Future of Artificial Kidney in Humans.Indian journal of nephrologyReview
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
Abstract
Diffusion-based bioartificial pancreas (BAP) devices are limited by poor islet viability and functionality due to inadequate mass transfer resulting in islet hypoxia and delayed glucose-insulin kinetics. While intravascular ultrafiltration-based BAP devices possess enhanced glucose-insulin kinetics, the polymer membranes used in these devices provide inadequate ultrafiltrate flow rates and result in excessive thrombosis. Here, we report the silicon nanopore membrane (SNM), which exhibits a greater hydraulic permeability and a superior pore size selectivity compared to polymer membranes for use in BAP applications. Specifically, we demonstrate that the SNM-based intravascular BAP with ∼10 and ∼40 nm pore sized membranes support high islet viability (>60%) and functionality (<15 minute insulin response to glucose stimulation) at clinically relevant islet densities (5700 and 11 400 IE per cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.